While historical response rates to single agent MMAE is ~10%, multiple myeloma cells typically have a low proliferative index (Ki67 median 4.4%)28, and therefore cell-cycle dependent drugs such as MMAE conjugates may be less effective for this cell population. This evidence concerns the gene MKI67 and plasma cell myeloma.